
Quest Diagnostics (DGX) Stock Forecast & Price Target
Quest Diagnostics (DGX) Analyst Ratings
Bulls say
Quest Diagnostics has demonstrated robust performance, with total revenue reaching $2.82 billion, reflecting a year-over-year growth of 13.1% and exceeding both internal and consensus estimates. The company reported a remarkable increase in cash flow from operations, up 63.1% year-over-year, bolstered by higher operating income and strategic benefits from recent initiatives. Additionally, the strong expansion in both physician and consumer-initiated testing channels highlights broad-based demand, with significant growth opportunities in advanced diagnostics and partnerships further supporting the positive outlook for the company's financial health.
Bears say
The negative outlook on Quest Diagnostics's stock stems from its reliance on clinical testing, which generates over 95% of its revenue, indicating vulnerability to fluctuations in demand and market conditions. Additionally, the reference to a pricing target based on an 18.0x multiple of 2027E adjusted EPS suggests concerns about the company's future earnings potential in a competitive environment. Lastly, the note about a marginal benefit from weather and a global IT outage in the prior year quarter may imply that past performance improvements could be unsustainable, raising doubts about consistent revenue growth going forward.
This aggregate rating is based on analysts' research of Quest Diagnostics and is not a guaranteed prediction by Public.com or investment advice.
Quest Diagnostics (DGX) Analyst Forecast & Price Prediction
Start investing in Quest Diagnostics (DGX)
Order type
Buy in
Order amount
Est. shares
0 shares